Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quigley Corporation has obtained positive preclinical results for its antiviral compound QR-435 in ocular and genital herpes.
Subscribe to our email newsletter
QR-435 has demonstrated antiviral activity against ocular and genital herpes in preclinical studies at a US university, indicating a new R&D path for the versatile antiviral compound. Quigley Pharma is currently negotiating with the university to undertake further trials.
The studies were designed to determine the in-vitro inhibitory activity of QR-435 versus two ocular isolates of herpes simplex virus – 1 (HSV-1) and 2 non-ocular isolates of herpes simplex virus – 2 (HSV-2).
The preclinical studies of QR-435 demonstrated reproducible potent direct antiviral activity against an ocular isolate of HSV-1. The compound also demonstrated similar potent direct antiviral activity against a second similar ocular isolate of HSV-1 and multiple clinical genital isolates of HSV-2.
“After review of the impressive results of these in vitro studies, QR-435 appears to be an excellent candidate for further research as an anti-herpes drug for both the treatment of ocular HSV-1 and genital HSV-2,” stated Dr Edwin Keates, of Northern Ophthalmic Associates and a member of Quigley Pharma’s medical advisory board.